Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADC119
- Development stage
- Phase 1
- Lead developer
- AIDEA PHARMA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ADC119 is an investigational, oral, once-daily, single-tablet fixed-dose combination regimen being developed by Jiangsu Aidea Pharmaceutical for the treatment of antiretroviral-naïve adult patients with HIV-1 infection. The formulation combines three active antiretroviral agents: ainuovirine, a novel third-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed in China, alongside two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), emtricitabine and tenofovir alafenamide. Mechanistically, the combination targets the HIV-1 reverse transcriptase enzyme, blocking the transcription of viral RNA into DNA and thereby suppressing viral replication. By combining an NNRTI with a dual-NRTI backbone in a single tablet, ADC119 aims to simplify treatment regimens, improve patient adherence, and reduce the risk of viral resistance.
- Other names
- ainuovirine + emtricitabine + tenofovir alafenamideainuovirine/emtricitabine/tenofovir alafenamide
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on ADC119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADC119.